The latest approval is welcome news for pancreatic cancer patients, who have few treatment options beyond chemotherapy. While Merck & Co.’s PD-1 inhibitor Keytruda (pembrolizumab) and its AstraZeneca-partnered PARP drug Lynparza (olaparib) are both approved for the disease, they’re limited to small, genetically defined populations. For more, see ViewPoints: Ipsen success provides epitaph for Merrimack.
NAPOLI 3 enrolled 770 patients who had not previously received chemotherapy. The Onivyde regimen achieved overall survival of 11.1 months, compared with 9.2 months for the comparator arm, meeting the primary endpoint. Patients who received NALIRIFOX also had a median progression-free survival of 7.4 months, versus 5.6 months for the chemotherapy-only cohort.
Ipsen acquired US rights to OnivydeOnivyde from Merrimack Pharmaceuticals in 2017; with the first-line approval now in hand, the latter stands to receive a $225-million milestone payment.
Servier is responsible for commercialisation of OnivydeOnivyde outside of the US, as well as outside of Taiwan, where PharmaEngine has rights.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.